PD-L1 Expression Level of Primary Tumor as a Predictor of Local Control and Symptomatic Radiation Necrosis in Patients With Brain Metastases Undergoing SRS/fSRT With Concurrent Immunotherapy
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Alexander, G.S.Savla, B.
Berg, L.J.
Sun, K.
Remick, J.S.
Kowalski, E.S.
Chen, S.
Lamichhane, N.
Regine, W.F.
Mishra, M.V.
Date
2021-11Journal
International Journal of Radiation Oncology - Biology - PhysicsPublisher
ElsevierType
Abstract
Metadata
Show full item recordAbstract
PD-L1 is often overexpressed in the tumor microenvironment to dampen host immune response and allow tumor proliferation. Radiation works partially through the immune system, but the correlation between PD-L1 expression in primary tumors and oncologic outcomes for metastatic lesions treated with SRS with concurrent immunotherapy (ICI) is unknown. We seek to evaluate the association of PD-L1 expression level of the primary tumor in patients undergoing SRS/fSRT with local control and symptomatic radiation necrosis.Rights/Terms
Copyright © 2021 Published by Elsevier Inc.Identifier to cite or link to this item
http://hdl.handle.net/10713/18475ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2021.07.1521